Effects of "Tiangui No.1" on the treatment compliance in female patients with schizophrenia

Zhang Shiqiao; Zhao Xingfu; Qiao Yunshuan; Cui Weidong; Jin Guixing

doi:10.3969/j.issn.1009-6574.2018.12.011

Abstract：Objective? To investigate the effects of "Tiangui No. 1" on the compliance of female schizophrenic patients treated with risperidone. Methods? A total of 100 female patients treated in the outpatient department of Hengshui Psychiatric Hospital were recruited during January 2017 to February 2018. All the research subjects were randomly assigned into research group (n=51) and control group (n=49). Patients in the research group were treated with "Tiangui No. 1" combined with risperdone, while the patients in the control group were prescribed with risperidone alone for four sessions with 14 days a session. The severity of disease, adverse drug reactions (Prolactin, weight, nausea, abdominal distension, rash, etc.), overall quality of life, treatment satisfaction and medication compliance were evaluated at 8th week and 6th month. Results? Prolctin and weight of the research group after intervention were lower than those of the control group, and the difference was statistically significant (P＜0.05). There was no significant difference between the two groups in the severity of disease, adverse drug reactions (nausea, abdominal distension and rash) (P＞0.05). The overall quality of life, treatment satisfaction and medication compliance of the research group were higher than those of the control group after treatment, and the differences were statistically significant (P＜ 0.05). Conclusions? "Tiangui No. 1" can significantly reduce prolactin levels caused by antipsychotic drugs, improve menstrual disorders, reduce weight gain, improve quality of life, increase drug treatment satisfaction, thereby improving patients' treatment compliance.